Attached files
| file | filename |
|---|---|
| EX-99.4 - EXHIBIT 99.4 - PLx Pharma Inc. | v464526_ex99-4.htm |
| EX-99.3 - EXHIBIT 99.3 - PLx Pharma Inc. | v464526_ex99-3.htm |
| EX-99.2 - EXHIBIT 99.2 - PLx Pharma Inc. | v464526_ex99-2.htm |
| EX-99.1 - EXHIBIT 99.1 - PLx Pharma Inc. | v464526_ex99-1.htm |
| EX-23.1 - EXHIBIT 23.1 - PLx Pharma Inc. | v464526_ex23-1.htm |
| EX-10.5 - EXHIBIT 10.5 - PLx Pharma Inc. | v464526_ex10-5.htm |
| EX-10.4 - EXHIBIT 10.4 - PLx Pharma Inc. | v464526_ex10-4.htm |
| EX-10.3 - EXHIBIT 10.3 - PLx Pharma Inc. | v464526_ex10-3.htm |
| EX-10.2 - EXHIBIT 10.2 - PLx Pharma Inc. | v464526_ex10-2.htm |
| EX-10.1 - EXHIBIT 10.1 - PLx Pharma Inc. | v464526_ex10-1.htm |
| EX-3.2 - EXHIBIT 3.2 - PLx Pharma Inc. | v464526_ex3-2.htm |
| EX-3.1 - EXHIBIT 3.1 - PLx Pharma Inc. | v464526_ex3-1.htm |
| 8-K - 8-K - PLx Pharma Inc. | v464526_8k.htm |
Exhibit 16.1
April 19, 2017
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-7561
Dear Sirs/Madams:
We have read the statements made by PLx Pharma Inc. (formerly Dipexium Pharmaceuticals, Inc.), which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K, as part of the Form 8-K of PLx Pharma Inc. (formerly Dipexium Pharmaceuticals, Inc.) dated April 19, 2017. We agree with the statements concerning our Firm in such Form 8-K.
Very truly yours,
/s/ CohnReznick LLP